Copenhagen, Denmark, 18 January 2023 - Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments and critical care therapies has appointed Hanne Junggreen as Corporate Vice President of Global Quality from 1 January 2023.
Hanne has been with Xellia for more than 25 years and has contributed greatly to Xellia through her multi-faceted roles in the organization over the years. Hanne has held various senior leadership positions since joining Xellia both within Quality and Production across Active Pharmaceutical Ingredient and Aseptic Drug Product manufacturing. Joining Xellia’s Leadership Team, Hanne will be based at the Company’s headquarters in Copenhagen, Denmark.
Carl-Åke Carlsson, CEO and President at Xellia Pharmaceuticals, commented:
“We are very pleased to appoint and welcome Hanne Junggreen as our new Corporate Vice President, Global Quality. Hanne will be a key asset to the team, bringing with her extensive managerial experience within Quality and Manufacturing from key senior leadership roles within the company.”
Hanne graduated as a Chemical Engineer from the University of Southern Denmark.
Download as PDF
For more information, please contact:
Xellia Pharmaceuticals
Carl-Åke Carlsson, CEO
+45 32 64 55 00
Instinctif Partners (International media relations)
Melanie Toyne-Sewell / Rozi Morris
+44 (0) 20 7457 2020
xellia@instinctif.com